Analysts forecast that NuCana PLC (NASDAQ:NCNA) will announce ($0.26) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for NuCana’s earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.23). The firm is expected to announce its next earnings results on Monday, January 1st.

Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow NuCana.

Separately, Cowen reaffirmed a “buy” rating on shares of NuCana in a report on Wednesday, August 29th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. NuCana has an average rating of “Buy” and a consensus price target of $21.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sofinnova Ventures Inc bought a new position in NuCana in the 1st quarter worth approximately $88,293,000. Baillie Gifford & Co. boosted its holdings in NuCana by 2.2% in the 2nd quarter. Baillie Gifford & Co. now owns 655,450 shares of the company’s stock valued at $12,454,000 after purchasing an additional 14,330 shares during the period. Woodford Investment Management Ltd boosted its holdings in NuCana by 27.3% in the 2nd quarter. Woodford Investment Management Ltd now owns 420,000 shares of the company’s stock valued at $7,980,000 after purchasing an additional 90,000 shares during the period. Asymmetry Capital Management L.P. boosted its holdings in NuCana by 18.4% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 47,872 shares of the company’s stock valued at $910,000 after purchasing an additional 7,424 shares during the period. Finally, Alps Advisors Inc. boosted its holdings in NuCana by 8.2% in the 2nd quarter. Alps Advisors Inc. now owns 46,269 shares of the company’s stock valued at $879,000 after purchasing an additional 3,508 shares during the period. 24.42% of the stock is owned by institutional investors.

Shares of NuCana stock traded up $0.29 on Wednesday, reaching $22.70. 736 shares of the company traded hands, compared to its average volume of 20,677. NuCana has a 52 week low of $9.32 and a 52 week high of $32.00. The company has a market capitalization of $712.89 million and a P/E ratio of -21.04.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.

See Also: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NuCana (NASDAQ:NCNA)

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.